GNOM vs IBB

Key Takeaways

• GNOM offers concentrated thematic exposure to genomics and advanced biotechnology applications, while IBB provides broader diversification across the entire biotechnology sector.
• GNOM holds approximately 50 securities with a 0.50% expense ratio; IBB holds roughly 250 securities at a lower 0.44% expense ratio.
• Both ETFs are passively managed and focused on healthcare, yet GNOM emphasizes gene editing, sequencing, and computational genomics, whereas IBB tracks a comprehensive NYSE Biotechnology Index.
• GNOM’s top holdings tend to include smaller, innovation-driven companies such as Guardant Health and Illumina; IBB’s largest positions feature established leaders including Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
• Structural differences result in distinct risk profiles: GNOM exhibits higher concentration risk, while IBB delivers greater sector breadth and potentially lower volatility through diversification.
• In the current market environment, both funds respond to biotechnology innovation cycles, regulatory developments, and capital flows into life sciences research.

Introduction

Global X Genomics & Biotechnology ETF (GNOM) and iShares Biotechnology ETF (IBB) both target the healthcare sector yet pursue different strategies within biotechnology. GNOM narrows its mandate to companies advancing genomic science, while IBB captures a wide cross-section of biotechnology firms. Investors comparing the two ETFs can evaluate trade-offs between focused thematic exposure and broad sector representation, particularly as advances in gene therapy and precision medicine continue to shape the industry. The ETFs do not compete directly but instead serve as complementary or alternative vehicles for gaining biotech exposure aligned with specific risk tolerances and investment objectives.

Global X Genomics & Biotechnology ETF (GNOM) Overview

GNOM is a passively managed thematic ETF that seeks to track the Solactive Genomics Index. The index selects companies deriving significant revenue from gene editing, genomic sequencing, genetic medicine and therapies, computational genomics, and related biotechnology activities. The fund typically holds around 50 securities and maintains an expense ratio of 0.50%. Top holdings often include Guardant Health, Illumina, Twist Bioscience, 10x Genomics, and Natera. Sector allocation is concentrated in healthcare, with the majority of assets in pharmaceuticals, biotechnology, and life sciences. GNOM employs full replication of its underlying index and rebalances periodically to maintain alignment with index constituents. Its narrower focus results in higher concentration compared with broad biotech vehicles.

iShares Biotechnology ETF (IBB) Overview

IBB is a passively managed ETF designed to track the NYSE Biotechnology Index, which comprises U.S.-listed equities primarily engaged in biotechnology research, development, and commercialization. The fund holds approximately 250 securities and charges an expense ratio of 0.44%. Leading holdings commonly feature Amgen, Vertex Pharmaceuticals, Gilead Sciences, Regeneron Pharmaceuticals, and argenx. Sector exposure centers on biotechnology, supplemented by life sciences tools and services as well as select pharmaceutical names. IBB uses a representative sampling approach and rebalances to track its benchmark. Its larger asset base and broader holdings provide greater diversification across market-capitalization tiers within the biotechnology space.

Industry and Thematic Backdrop

The biotechnology sector continues to benefit from ongoing innovation in gene and cell therapies, precision oncology, and next-generation sequencing technologies. Regulatory pathways for novel treatments, intellectual-property developments, and capital allocation toward research and development remain key catalysts. Macroeconomic factors such as interest-rate expectations and overall risk appetite influence funding availability for early-stage companies. Both GNOM and IBB operate within this environment, where scientific breakthroughs can drive long-term growth while clinical setbacks and reimbursement challenges introduce volatility. Sector risks include high research-and-development costs, lengthy approval timelines, and competition from larger pharmaceutical firms.

Performance and Positioning Comparison

Over recent market cycles, GNOM’s concentrated thematic approach has produced distinct performance patterns relative to IBB’s broader biotechnology exposure. GNOM tends to exhibit greater sensitivity to developments in genomics-specific technologies and smaller-cap innovators, resulting in higher volatility during periods of sector rotation. IBB, with its emphasis on established biotechnology leaders, has generally demonstrated more stable behavior across earnings seasons and macroeconomic shifts. Relative positioning reflects these structural differences: GNOM aligns with investors seeking targeted exposure to genomic advancements, while IBB suits those preferring diversified participation in the wider biotechnology industry. Both funds respond to common drivers such as clinical trial outcomes and capital flows into life sciences, yet their differing concentration levels influence how they navigate market cycles.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking to compare or monitor ETFs like GNOM and IBB may find the platform useful for generating additional insights.

Tickeron AI Verdict

Based on observable structural characteristics, Tickeron’s AI would currently assign a modest preference to IBB. The ETF’s lower expense ratio, substantially larger number of holdings, and broader diversification across biotechnology companies provide a more balanced risk profile while still capturing sector momentum. GNOM’s thematic focus delivers compelling exposure to genomics innovation but carries higher concentration risk. In probabilistic terms, IBB’s combination of cost efficiency and diversification positions it as the more resilient choice across varying market conditions within the current biotechnology environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations